Menu
Search
|

Menu

Close
X

Aileron Therapeutics Inc ALRN.OQ (NASDAQ Stock Exchange Global Market)

4.28 USD
+0.06 (+1.42%)
As of Jul 20
chart
Previous Close 4.22
Open 4.24
Volume 11,447
3m Avg Volume 17,300
Today’s High 4.50
Today’s Low 4.20
52 Week High 15.34
52 Week Low 4.09
Shares Outstanding (mil) 14.71
Market Capitalization (mil) 214.98
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.515
FY17
-1.539
FY16
-1.237
FY15
-0.445
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
--
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
--
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Jeffrey Bailey
Chairman of the Board, Since 2018
Salary: --
Bonus: --
John Longenecker
Interim President, Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Evan Lippman
Chief Financial Officer and Business Officer, Senior Vice President, Since 2015
Salary: --
Bonus: --
Manuel Aivado
Senior Vice President and Chief Medical Officer, Since 2014
Salary: --
Bonus: --
D. Allen Annis
Vice President - Biophysical and Analytical Technologies, Since 2007
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

281 Albany St
CAMBRIDGE   MA   02139-4230

Phone: +1617.9950900

Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.

SPONSORED STORIES